Literature DB >> 20471725

Effect of butyrate enemas on inflammation and antioxidant status in the colonic mucosa of patients with ulcerative colitis in remission.

Henrike M Hamer1, Daisy M A E Jonkers, Steven A L W Vanhoutvin, Freddy J Troost, Ger Rijkers, Adriaan de Bruïne, Aalt Bast, Koen Venema, Robert-Jan M Brummer.   

Abstract

BACKGROUND & AIMS: Butyrate, produced by colonic fermentation of dietary fibers is often hypothesized to beneficially affect colonic health. This study aims to assess the effects of butyrate on inflammation and oxidative stress in subjects with chronically mildly elevated parameters of inflammation and oxidative stress.
METHODS: Thirty-five patients with ulcerative colitis in clinical remission daily administered 60 ml rectal enemas containing 100mM sodium butyrate (n=17) or saline (n=18) during 20 days (NCT00696098). Before and after the intervention feces, blood and colonic mucosal biopsies were obtained. Parameters of antioxidant defense and oxidative damage, myeloperoxidase, several cytokines, fecal calprotectin and CRP were determined.
RESULTS: Butyrate enemas induced minor effects on colonic inflammation and oxidative stress. Only a significant increase of the colonic IL-10/IL-12 ratio was found within butyrate-treated patients (p=0.02), and colonic concentrations of CCL5 were increased after butyrate compared to placebo treatment (p=0.03). Although in general butyrate did not affect colonic glutathione levels, the effects of butyrate enemas on total colonic glutathione appeared to be dependent on the level of inflammation.
CONCLUSION: Although UC patients in remission were characterized by low-grade oxidative stress and inflammation, rectal butyrate enemas showed only minor effects on inflammatory and oxidative stress parameters.
Copyright © 2010 Elsevier Ltd and European Society for Clinical Nutrition and Metabolism. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20471725     DOI: 10.1016/j.clnu.2010.04.002

Source DB:  PubMed          Journal:  Clin Nutr        ISSN: 0261-5614            Impact factor:   7.324


  51 in total

1.  Interleukin-12 (IL-12)/IL-10 ratio as a marker of disease severity in Crimean-Congo hemorrhagic fever.

Authors:  Dionysios C Watson; Maria Sargianou; George Panos
Journal:  Clin Vaccine Immunol       Date:  2012-05

2.  Immunodeficiency and autoimmune enterocolopathy linked to NFAT5 haploinsufficiency.

Authors:  Brigid S Boland; Christella E Widjaja; Asoka Banno; Bing Zhang; Stephanie H Kim; Samantha Stoven; Michael R Peterson; Marilyn C Jones; H Irene Su; Sheila E Crowe; Jack D Bui; Samuel B Ho; Yoshinaga Okugawa; Ajay Goel; Eric V Marietta; Mahdieh Khosroheidari; Kristen Jepsen; Jose Aramburu; Cristina López-Rodríguez; William J Sandborn; Joseph A Murray; Olivier Harismendy; John T Chang
Journal:  J Immunol       Date:  2015-02-09       Impact factor: 5.422

3.  Effectiveness of probiotic therapy for the prevention of relapse in patients with inactive ulcerative colitis.

Authors:  Yasushi Yoshimatsu; Akihiro Yamada; Ryuichi Furukawa; Koji Sono; Aisaku Osamura; Kentaro Nakamura; Hiroshi Aoki; Yukiko Tsuda; Nobuo Hosoe; Nobuo Takada; Yasuo Suzuki
Journal:  World J Gastroenterol       Date:  2015-05-21       Impact factor: 5.742

4.  Epigenomics and the microbiota.

Authors:  Theresa Alenghat
Journal:  Toxicol Pathol       Date:  2014-10-20       Impact factor: 1.902

5.  Colonic butyrate- algesic or analgesic?

Authors:  P Kannampalli; R Shaker; J N Sengupta
Journal:  Neurogastroenterol Motil       Date:  2011-11       Impact factor: 3.598

6.  Intraperitoneal administration of butyrate prevents the severity of acetic acid colitis in rats.

Authors:  Joshua J Malago; Catherine L Sangu
Journal:  J Zhejiang Univ Sci B       Date:  2015-03       Impact factor: 3.066

Review 7.  Pathobiology and potential therapeutic value of intestinal short-chain fatty acids in gut inflammation and obesity.

Authors:  Jessica Soldavini; Jonathan D Kaunitz
Journal:  Dig Dis Sci       Date:  2013-07-10       Impact factor: 3.199

8.  The microbial metabolite butyrate regulates intestinal macrophage function via histone deacetylase inhibition.

Authors:  Pamela V Chang; Liming Hao; Stefan Offermanns; Ruslan Medzhitov
Journal:  Proc Natl Acad Sci U S A       Date:  2014-01-03       Impact factor: 11.205

9.  Whole-body pharmacokinetics of HDAC inhibitor drugs, butyric acid, valproic acid and 4-phenylbutyric acid measured with carbon-11 labeled analogs by PET.

Authors:  Sung Won Kim; Jacob M Hooker; Nicola Otto; Khaing Win; Lisa Muench; Colleen Shea; Pauline Carter; Payton King; Alicia E Reid; Nora D Volkow; Joanna S Fowler
Journal:  Nucl Med Biol       Date:  2013-07-29       Impact factor: 2.408

10.  Use of butyrate or glutamine in enema solution reduces inflammation and fibrosis in experimental diversion colitis.

Authors:  Rodrigo Goulart Pacheco; Christiano Costa Esposito; Lucas C M Müller; Morgana T L Castelo-Branco; Leonardo Pereira Quintella; Vera Lucia A Chagas; Heitor Siffert P de Souza; Alberto Schanaider
Journal:  World J Gastroenterol       Date:  2012-08-28       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.